Forvisirvat (SP-624)
Redefining depression treatment with first-in-class epigenetic innovation
THE PROBLEM
Depression continues to be an epidemic around the world, despite available treatments. Arrivo is interested in the differences in depression between women and men. Literature has long suggested that women and men manifest their depressive symptoms differently, with women tending to display symptoms more outwardly such as sadness, crying, fatigue; whereas men tend to be more inward focused, with symptoms such as irritability, anger and feelings of self-loathing.
Recent published literature suggests that one potential reason for the differences by sex in depression could be that women and men have opposite or divergent gene expression when depressed.
THE COMPOUND
SP-624 is a SIRT6 activator which has an epigenetic mechanism of action. SIRT6 is a gene silencer, that is believed to play a role in DNA repair, mitochondrial health, inflammation and glucose homeostasis.
Slide to Adjust The Before and After Effects of SP-624
RELEVANT PUBLICATIONS
- A phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder
- Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies of the Safety,Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP-624 in Healthy Adults
- Aging epigenome begins to change in age-related neurodegenerative diseases
- SIRT6 is a key regulator of mitochondrial function in the brain
- Restoration of energy homeostasis by SIRT6 extends healthy lifespan
- Sirtuin 6: linking longevity with genome and epigenome stability
- Complex role of SIRT6 in NF-kB pathway regulation
- Opposite molecular signatures of depression in men and women
